Relationship between modeling technique and reported outcomes: case studies in models for the treatment of schizophrenia

References

• National Institute for Health and Clinical Excellence. Schizophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. CG82; 2011. Available from: http://guidance.nice.org.uk/CG82 [Last accessed 17 July 2013]
   Google Scholar
• Heres S, Davis J, Maino K, et al. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry 2006;163(2):185-94
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. Erratum in: N Engl J Med 2010;363(11):1092-1093. N Engl J Med 2005;353(12):1209-23
   Google Scholar
• Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003;361(9369):1581-9
   PubMed Web of Science ®Google Scholar
• Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;382(9896):951-62
   PubMed Web of Science ®Google Scholar
• Raschi E, Poluzzi E, Godman B, et al. Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe. PLoS One 2013;8(11):e81208
   Web of Science ®Google Scholar
• Caro JJ. Pharmacoeconomic analyses using discrete event simulation. Pharmacoeconomics 2005;23(4):323-32
   PubMed Web of Science ®Google Scholar
• Caro JJ, Möller J, Getsios D. Discrete event simulation: the preferred technique for health economic evaluations? Value Health 2010;13(8):1056-60
   PubMed Web of Science ®Google Scholar
• Heeg B, Buskens E, Knapp M, et al. Modeling the treated course of schizophrenia: development of a discrete event simulation model. Pharmacoeconomics 2005;23(Suppl 1):17-33
   PubMed Web of Science ®Google Scholar
• Caro JJ, Briggs AH, Siebert U, Kuntz KM; ISPOR-SMDM Modeling Good Research Practices Task Force. Modeling good research practices–overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–1. Value Health 2012;15(6):796-803
   PubMed Web of Science ®Google Scholar
• Heeg BM, Damen J, Buskens E, et al. Modelling approaches: the case of schizophrenia. Pharmacoeconomics 2008;26(8):633-48
   PubMed Web of Science ®Google Scholar
• Alexeyeva I, Mauskopf J, Earnshaw SR, et al. Comparing olanzapine and ziprasidone in the treatment of schizophrenia: a case study in modeling [structured abstract]. J Med Econ 2001;4:179-92
   Google Scholar
• Almond S, O'Donnell O. Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol. Pharmacoeconomics 2000;17(4):383-9
   Google Scholar
• Bagnall AM, Jones L, Ginnelly L, et al. A systematic review of atypical antipsychotic drugs in schizophrenia [structured abstract]. Health Technol Assess 2003;7(13):1-193
   PubMedGoogle Scholar
• Beard S, Lothgren M, Giudi L, et al. A cost-effectiveness comparison of olanzapine and risperidone in the treatment of schizophrenia in Italy [abstract no. PMH 3]. Value Health 2002;5(6):515
   Google Scholar
• Beard SM, Maciver F, Clouth J, Ruther E. A decision model to compare health care costs of olanzapine and risperidone treatment for schizophrenia in Germany. Eur J Health Econ 2006;7(3):165-72
   Google Scholar
• Bobes J, Canas F, Rejas J, Mackell J. Economic consequences of the adverse reactions related with antipsychotics: an economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol in Spain. Prog Neuropsychopharmacol Biol Psychiatry 2004;28(8):1287-97
   PubMed Web of Science ®Google Scholar
• Bounthavong M, Okamoto MP. Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia. J Eval Clin Pract 2007;13(3):453-60
   Google Scholar
• Chue PS, Heeg B, Buskens E, van Hout BA. Modeling the impact of compliance on the costs and effects of long-acting risperidone in Canada. Pharmacoeconomics 2005;23(Suppl 1):62-74
   Google Scholar
• Colombo GL, Caruggi M, Di Matteo S, Rossi A. An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia. Neuropsychiatr Dis Treat 2008;4(5):967-76
   PubMedGoogle Scholar
• Crowley S, Schrower R, Neville AM. Cost-effectiveness analysis in the Australian setting of risperidone long-acting injection for the treatment of patients with schizophrenia who are partially adherent to their medication [abstract no. PMH 30]. Value Health 2004;7(6):781-2
   Google Scholar
• De Graeve D, Smet A, Mehnert A, et al. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis. Pharmacoeconomics 2005;23(Suppl 1):35-47
   PubMed Web of Science ®Google Scholar
• De Hert M, Van Dijk M, Lecomte P, Nuyts G. A one year cost-effectiveness model for the treatment of chronic schizophrenia in Belgium. Eur Neuropsychopharmacol 2000;10(Suppl 3):S316
   Google Scholar
• Dilla T, O'Donohoe P, Möller J, et al. Cost-effectiveness of long-acting olanzapine versus long-acting risperidone in patients with schizophrenia in Spain [abstract no. PMH31]. Value Health 2011;14(3):A191
   Google Scholar
• Edwards NC, Locklear JC, Rupnow MF, Diamond RJ. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. Pharmacoeconomics 2005;23(Suppl 1):75-89
   PubMed Web of Science ®Google Scholar
• Edwards NC, Rupnow MF, Pashos CL, et al. Cost-effectiveness model of long-acting risperidone in schizophrenia in the US. Pharmacoeconomics 2005;23(3):299-314
   Google Scholar
• Edwards NC, Pesa J, Meletiche DM, et al. One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophrenia. Curr Med Res Opin 2008;24(12):3341-55
   PubMed Web of Science ®Google Scholar
• Einarson TR, Vicente C, Zilbershtein R, Piwko C. A cost-effectiveness analysis of paliperidone palmitate versus olanzapine pamoate in the treatment of schizophrenia in Norway [abstract no. PMH35]. Value Health 2011;14(7):A292-3
   Google Scholar
• Elsaid KA, Angelini M. Costs and effects of iloperidone compared with olanzapine and haloperidol in patients with acute schizophrenia: results from a cost-effectiveness Markov model [abstract no. PMH50]. Value Health 2010;13(3):A113
   Google Scholar
• Furiak NM, Ascher-Svanum H, Klein RW, et al. Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States. Cost Eff Resour Alloc 2009;7:4
   PubMedGoogle Scholar
• Furiak NM, Ascher-Svanum H, Klein RW, et al. Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model. Curr Med Res Opin 2011;27(4):713-30
   PubMed Web of Science ®Google Scholar
• Geitona M, Kousoulakou H, Ollandezos M, et al. Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study. Ann Gen Psychiatry 2008;7:16
   PubMedGoogle Scholar
• Graham CN, Mauskopf JA, Lawson AH, et al. Updating and confirming an industry-sponsored pharmacoeconomic model: comparing two antipsychotics in the treatment of schizophrenia. Value Health 2012;15:55-64
   PubMed Web of Science ®Google Scholar
• Greenhalgh J, Knight C, Hind D, et al. Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: systematic reviews and economic modeling studies. Health Technol Assess 2005;9(9):1-156. iii-iv
   PubMedGoogle Scholar
• Hansen K, Francois C, Toumi M, Lancon C. A pharmacoeconomic evaluation of zuclopenthixol compared with haloperidol and risperidone in the treatment of schizophrenia. Eur J Health Econ 2002;3(3):173-9
   PubMedGoogle Scholar
• Hensen M, Heeg B, Lothgren M, van Hout B. Cost effectiveness of long-acting risperidone in Sweden. Appl Health Econ Health Policy 2010;8(5):327-41
   Google Scholar
• Heeg BM, van Aalst G, van den Arend IJ, et al. A discrete events model of long-term outcomes and cost of treatment with long acting risperidone in schizophrenia [abstract no. PMH5]. Value Health 2003;5(6):515-16
   Google Scholar
• Heeg BM, Antunes J, Figueira ML, et al. Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise. Curr Med Res Opin 2008;24(2):349-58
   PubMed Web of Science ®Google Scholar
• Jones MA, Meier GC. A cost utility analysis of first line antipsychotics for the prevention of schizophrenia relapse in the United Kingdom [abstract no. PMH38]. Value Health 2010;13(7):A452
   Google Scholar
• Kasteng F, Eriksson J, Sennfalt K, Lindgren P. Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder. Acta Psychiatr Scand 2011;124(3):214-25
   Google Scholar
• Kim BRM, Lee HJ, Park BH, et al. Cost-effectiveness of sertindole among atypical antipsychotics in the treatment of schizophrenia in South Korea [abstract no. PMH10]. Value Health 2010;13(7):A554
   Google Scholar
• Kim K, Aas E. Cost-effectiveness analysis of olanzapine and risperidone in Norway. J Ment Health Policy Econ 2011;14(3):125-35
   Google Scholar
• Kim BRM, Lee TJ, Woo JM, et al. Cost-utility analysis of paliperidone palmitate long acting injection (PLAI) vs oral atypical antipsychotics in non-adherent schizophrenia patients [abstract no. PMH42]. Value Health 2011;14(7):A294
   Google Scholar
• Kostrzewska K, Lis J, Glasek M, et al. Cost-utility of amisulpride compared with first generation antipsychotics in treatment of schizophrenia in Poland [abstract no. PMH34]. Value Health 2011;14(7):A292
   Google Scholar
• Lam A, Heeg B. Canadian cost-effectiveness analysis of long-acting risperidone versus oral atypical and conventional depot antipsychotics in patients with schizophrenia at high-risk of non-compliance: updated based on new clinical data [abstract no. PMH55]. Value Health 2010;13(3):A114
   Google Scholar
• Laux G, Heeg B, van Hout BA, Mehnert A. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany. Pharmacoeconomics 2005;23(Suppl 1):49-61
   PubMed Web of Science ®Google Scholar
• Lecomte P, De Hert M, Van Dijk M, et al. A 1-year cost-effectiveness model for the treatment of chronic schizophrenia with acute exacerbations in Belgium. Value Health 2000;3(1):1-11
   PubMedGoogle Scholar
• Lindner LM, Marasciulo AC, Farias MR, Grohs GE. Economic evaluation of antipsychotic drugs for schizophrenia treatment within the Brazilian healthcare system. Rev Saude Publica 2009;43(Suppl 1):62-9
   PubMedGoogle Scholar
• Lindström E, Eberhard J, Fors BM, et al. A pharmacoeconomic analysis of sertindole in the treatment of schizophrenia in Sweden. Nord J Psychiatry 2011;65(6):403-13
   PubMed Web of Science ®Google Scholar
• Magnus A, Carr V, Mihalopoulos C, et al. Assessing cost-effectiveness of drug interventions for schizophrenia. Aust N Z J Psychiatry 2005;39(1-2):44-54
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Cragin L, Sorensen S, et al. Comparison of the metabolic and economic consequences of long-term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in Canada: a cost-effectiveness analysis. J Eval Clin Pract 2010;16(4):744-55
   Google Scholar
• Obradovic M, Mrhar A, Kos M. Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia. Int J Clin Pract 2007;61(12):1979-88
   Google Scholar
• Oh PI, Iskedjian M, Addis A, et al. Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis. Pharmacoeconomics 2001;8(4):199-206
   Google Scholar
• Oh PI, Lanctot KL, Mittmann N, et al. Cost-utility of risperidone compared with standard conventional antipsychotics in chronic schizophrenia. J Med Econ 2001;4(1-4):137-56
   Google Scholar
• Palmer CS, Brunner E, Ruiz-Flores LG, et al. A cost-effectiveness clinical decision analysis model for treatment of schizophrenia. Arch Med Res 2002;33(6):572-80
   PubMed Web of Science ®Google Scholar
• Pudas H, Hemels M, Mehnert A, et al. The cost-effectiveness of paliperidone palmitate compared to olanzapine pamoate in the treatment of schizophrenia in Sweden [abstract no. PMH2]. Value Health 2011;14(7):A560-1
   Google Scholar
• Reyes-Lopez A, Querol J. Cost-effectiveness of paliperidone palmitate for the treatment of schizophrenia in Mexico [abstract no. PMH3]. Value Health 2011;14(7):A561
   Google Scholar
• Schrover R, Crowley S, Neville A. Cost-effectiveness analysis of risperidone long acting injection (Risperdal Consta®) for the treatment of patients with schizophrenia who are partially medication adherent in Australia [abstract]. Med Decis Making 2006;26:E67
   Google Scholar
• Tilden D, Aristides M, Meddis D, Burns T. An economic assessment of quetiapine and haloperidol in patients with schizophrenia only partially responsive to conventional antipsychotics. Clin Ther 2002;24(10):1648-67
   PubMed Web of Science ®Google Scholar
• Treur M, Baca E, Bobes J, et al. The cost-effectiveness of paliperidone extended release in Spain. J Med Econ 2012;15(Suppl 1):26-34
   Google Scholar
• Vera-Llonch M, Delea TE, Richardson E, et al. Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model. Value Health 2004;7(5):569-84
   PubMed Web of Science ®Google Scholar
• Walczak J, Stelmachowski J, Obrzut G, Nogas G. Cost-utility analysis (CUA) of sertindole in the treatment of schizophrenia in Poland in a general population of schizophrenic patients and a population of patients intolerant to at least one other antipsychotic agent: a five-year Markov model [abstract no. PMH40]. Value Health 2010;13(7):A453
   Google Scholar
• National Institute for Health and Clinical Excellence. Schizophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. CG82; 2009. Available from: http://publications.nice.org.uk/schizophrenia-cg82 [Last accessed 17 July 2013]
   Google Scholar
• National Institute for Health and Clinical Excellence. Aripiprazole for schizophrenia in people aged 15 to 17 years. TA213; 2011. Available from: www.nice.org.uk/guidance/TA213 [Last accessed 17 July 2013]
   Google Scholar
• Scottish Medicines Consortium. Olanzapine 210 mg, 300 mg, 405 mg powder and solvent for prolonged release suspension for injection (Zypadhera). No. 624/10. Eli Lilly and Company Limited; 2010. Available from: www.scottishmedicines.org.uk/files/advice/olanzapine_ZypAdhera_FINAL_July_2010_amended_for_website.pdf [Last accessed 17 July 2013]
   Google Scholar
• Rabinowitz J, Lichtenberg P, Kaplan Z, et al. Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. Am J Psychiatry 2001;158(2):266-9
   Google Scholar
• Chouinard G, Albright PS. Economic and health state utility determination for schizophrenic patients treated with risperidone or haloperidol. J Clin Psychopharmacol 1997;17:298-307
   PubMed Web of Science ®Google Scholar
• Revicki DA, Shakespeare A, Kind P. Preferences for schizophrenia-related health states: a comparison of patients, caregivers and psychiatrists. Int Clin Psychopharmacol 1996;11(2):101-8
   Web of Science ®Google Scholar
• Seong SS, Choi CB, Sung YK, et al. Health-related quality of life using EQ-5D in Koreans. J Korean Rheum Assoc 2004;11(3):254-62
   Google Scholar
• Glennie JL. Pharmacoeconomic evaluations of clozapine in treatment-resistant schizophrenia and risperidone in chronic schizophrenia. Technology overview: pharmaceuticals. Canadian Coordinating Office for Health Technology Assessment; Ottawa; 1997
   Google Scholar
• Briggs A, Wild D, Lees M, et al. Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation. Health Qual Life Outcomes 2008;6:105
   PubMed Web of Science ®Google Scholar
• Lenert L, Sturley A, Rapaport M, et al. Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores. Schizophr Res 2004;71(1):155-65
   PubMed Web of Science ®Google Scholar
• Eddy DM, Hollingworth W, Caro JJ, et al. ISPOR−SMDM Modeling Good Research Practices Task Force. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–7. Value Health 2012;15(6):843-50
   PubMed Web of Science ®Google Scholar
• Chue P, Chue J. The cost-effectiveness of risperidone long-acting injection in the treatment of schizophrenia. Expert Rev Pharmacoecon Outcomes Res 2012;12(3):259-69
   PubMed Web of Science ®Google Scholar
• Achilla E, McCrone P. The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations. Appl Health Econ Health Policy 2013;11(2):95-106
   Google Scholar
• Scottish Medicines Consortium. Paliperidone prolonged-release tablets (INVEGA). SMC Drug ID: 453/08; 2008. Available from: www.scottishmedicines.org.uk/files/paliperidone__Invega__FINAL_March_2008_amended_010408.doc_for_website.pdf [Last accessed 17 July 2013]
   Google Scholar
• Scottish Medicines Consortium. Paliperidone palmitate (Xeplion). SMC Drug ID: 713/11; 2011. Available from: www.scottishmedicines.org.uk/files/advice/paliperidone_Xeplion_RESUBMISSION_FINAL_October_2011_for_website.pdf [Last accessed 17 July 2013]
   Google Scholar